Trial site
Hyogo Medical University Hospital
Hyōgo, 663-8501, JapanNot linked to an institution yet
- 13running trials
- 4closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 313 trials
- Phase 24 trials
- Status
- Active, not recruiting8 trials
- Completed4 trials
- Recruiting4 trials
- Not yet recruiting1 trial
- Lead sponsor
- Hoffmann-La Roche7 trials
- Janssen Research & Development, LLC3 trials
- Kite, A Gilead Company2 trials
- Daiichi Sankyo1 trial
- Eli Lilly and Company1 trial
- and 3 more
Running trials
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
NCT07623616· Phase 2· Kyowa Kirin Co., Ltd.· Source
Contact: Kyowa Kirin, Inc.
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498· Phase 3· Kite, A Gilead Company· Source
Recruiting
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995· Phase 3· Eli Lilly and Company· Source
Contact: Kenzo Tsuzuki (principal investigator)
Active, not recruiting
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
NCT06464991· Phase 3· Nanjing IASO Biotechnology Co., Ltd.· Source
Active, not recruiting
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06029972· Phase 2· Gilead Sciences· Source
Active, not recruiting
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732· Phase 3· Daiichi Sankyo· Source
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
NCT05371093· Phase 3· Kite, A Gilead Company· Source
Active, not recruiting
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893· Phase 3· Janssen Research & Development, LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error